News & Events about Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinias U.S. Patent No. 10,286,036. About LUPKYNIS LUPKYNIS...
Thinking about buying stock in First Wave BioPharma, GasLog Partners, Canoo, Aurinia Pharmaceuticals, or Rocket Lab USA? Thinking about buying stock in First Wave BioPharma, GasLog Partners, Canoo, Aurinia Pharmaceuticals, or Rocket Lab USA? PR Newswire NEW YORK, Jan. 25, 2023 NEW YORK, Jan. 25...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH Get Rating) (TSX:AUP) has been assigned a consensus rating of Moderate Buy from the six analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended December 31, 2022 was approximately $28.4 million and $134.0 million. For the three months ended...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun...